New horizons in the pharmacologic management of peptic ulceration.
Greatly improved understanding of the cellular basis for gastric acid secretion and gastroduodenal mucosal defense has led to a dramatic improvement in the pharmacologic treatment of peptic ulcer disease. The advances produced by cimetidine and ranitidine are being continued by a new generation of histamine receptor antagonists, as well as by other anti-ulcer agents. These new drugs, when used appropriately, will greatly expand the surgeon's ability to treat patients with peptic ulcer disease. A knowledge of the pathophysiologic characteristics of peptic ulceration and of the inherent limitations of each agent will become increasingly important for surgeons who treat these patients.
Debas
H T
HT
Mulholland
M W
MW
D000109:Acetylcholine / Q000502:physiology; D001562:Benzimidazoles / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002927:Cimetidine / Q000008:administration & dosage / Q000627:therapeutic use; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000188:drug therapy; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism; D005755:Gastrins / Q000502:physiology; D006632:Histamine / Q000502:physiology; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000378:metabolism; D010437:Peptic Ulcer / Q000188:drug therapy*; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use; D011976:Receptors, Muscarinic / Q000187:drug effects; D013268:Stimulation, Chemical; D013276:Stomach Ulcer / Q000188:drug therapy
D001562:Benzimidazoles; D005755:Gastrins; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D011976:Receptors, Muscarinic; D002927:Cimetidine; D006632:Histamine; D011899:Ranitidine; C036616:etintidine; D000109:Acetylcholine